'Know thyself' - host factors influencing cancer response to immune checkpoint inhibitors.
Lawley, Trevor D
Welsh, Sarah J
MetadataShow full item record
Gunjur, A., Manrique-Rincón, A. J., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022). 'Know thyself' - host factors influencing cancer response to immune checkpoint inhibitors.. J Pathol https://doi.org/10.1002/path.5907
Funder: General Sir John Monash Foundation; Id: http://dx.doi.org/10.13039/501100017475
Funder: Victorian Cancer Agency; Id: http://dx.doi.org/10.13039/100008018
Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard-of-care for the treatment of a wide variety of solid neoplasms. However, tumour responses remain unpredictable, experienced by only a minority of ICI recipients across malignancy types. Therefore, there is an urgent need for better predictive biomarkers to identify a priori the patients most likely to benefit from these therapies. Despite considerable efforts, only three such biomarkers are FDA-approved for clinical use, and all rely on the availability of tumour tissue for immunohistochemical staining or genomic assays. There is emerging evidence that host factors - for example, genetic, metabolic, and immune factors, as well as the composition of one's gut microbiota - influence the response of a patient's cancer to ICIs. Tantalisingly, some of these factors are modifiable, paving the way for co-therapies that may enhance the therapeutic index of these treatments. Herein, we review key host factors that are of potential biomarker value for response to ICI therapy, with a particular focus on the proposed mechanisms for these influences. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
biomarkers, germline, host, immune checkpoint inhibitors, immune system, immunotherapy, metabolome, microbiome, predictive, Humans, Immune Checkpoint Inhibitors, Immunologic Factors, Immunotherapy, Neoplasms, United Kingdom
Cancer Research UK (A25117)
External DOI: https://doi.org/10.1002/path.5907
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337361
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: firstname.lastname@example.org